Edgewise Therapeutics (NASDAQ:EWTX) (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.
At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases. By targeting the underlying mechanisms of podocyte injury, EWTX-101 is designed to reduce proteinuria and preserve renal function. The company also has earlier-stage programs exploring additional ion channel and intracellular targets, with the aim of expanding its portfolio into other rare diseases driven by calcium dysregulation.
Founded in 2018 by a team of drug development and neuroscience specialists, Edgewise completed its initial public offering in mid-2020. The company’s leadership comprises industry veterans with extensive experience in clinical translation, regulatory strategy and commercial planning. Edgewise operates primarily in the United States but is preparing for global clinical trials, seeking to establish collaborations and partnerships to facilitate broader patient access.
Looking ahead, Edgewise Therapeutics is advancing its lead asset through multiple clinical studies while progressing preclinical candidates toward IND filing. By combining deep scientific insight with a nimble development approach, the company aims to bring innovative therapies to patients who currently have limited or no treatment options.
